FDA.reportPublic FDA data

Velsipity 2 MG Oral Tablet

RxCUI
2668057
RxNorm name
Velsipity 2 MG Oral Tablet
Display name
Velsipity 2 MG Oral Tablet
Full name
Velsipity 2 MG Oral Tablet
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
VelsipityETRASIMODPfizer Laboratories Div Pfizer Inc65171e4a-d136-4abc-b08c-c40c1b486ff62025-08-18Warnings, Adverse reactionsExact identifier
rxcui: 2668057

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
65171e4a-d136-4abc-b08c-c40c1b486ff6Velsipity 2 MG Oral Tablet [PSN] · etrasimod 2 MG Oral Tablet [Velsipity] [SBD] · Velsipity 2 MG Oral Tablet [SY]34These highlights do not include all the information needed to use VELSIPITY safely and effectively. See full prescribing information for VELSIPITY. VELSIPITY™ (etrasimod) tablets, for oral use Initial U.S. Approval: 202320250818